Capsaicin topical cream (8%) for the treatment of myofascial pain syndrome

Myofascial pain syndrome is a common cause of musculoskeletal pain. The objective of this study was to evaluate the potential analgesic action of 8% capsaicin cream for topical use in patients with myofascial pain syndrome. Initially, cream formulations of PLA (Placebo) and CPS (Capsaicin 8%) were d...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian journal of anesthesiology (Elsevier) 2019-09, Vol.69 (5), p.432-438
Main Authors: Romero, Valéria, Lara, Juliana Rodrigues, Otero-Espinar, Francisco, Salgado, Manoel Henrique, Modolo, Norma Sueli Pinheiro, Barros, Guilherme Antonio Moreira de
Format: Article
Language:Portuguese
Subjects:
Administration, Topical
Analgesia
Capsaicin - administration & dosage
Double-Blind Method
Female
Humans
Male
Middle Aged
Myofascial Pain Syndromes - drug therapy
Ointments
Prospective Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myofascial pain syndrome is a common cause of musculoskeletal pain. The objective of this study was to evaluate the potential analgesic action of 8% capsaicin cream for topical use in patients with myofascial pain syndrome. Initially, cream formulations of PLA (Placebo) and CPS (Capsaicin 8%) were developed and approved according to the current requirements of the health authority agency. The 40 participating patients were randomly assigned to the PLA and CPS groups in a double-blind fashion. Before the creams were topically administered, according to the allocation group, the local anesthetic was used for a period of 50minutes directly in the area of interest. The cream was applied to the area of the skin over the trigger point, represented by the area with pain at palpation, in an amount of 10g for 30minutes in a circular area of 24 mm diameter. Subsequently, the cream was removed and the skin tolerability parameters were evaluated. The pain was measured before and during the formulation application, as well as at 1 hour, 7 days, 30 days, and 60 days after the procedure, evaluated using a verbal numerical scale (from 0 to 10: with 0=no pain and 10=worst pain imaginable). No patient in PLA Group had hyperemia or burning sensation at the site of application, while 85% of patients in CPS Group had hyperemia or burning sensation at 15minutes. These complaints disappeared 24hours after the cream was removed. The pain score in CPS Group decreased steadily up to the 60 day of evaluation (p
ISSN:1806-907X
2352-2291
DOI:10.1016/j.bjan.2019.06.008